MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.clgc.2026.102539

Медицинская библиотека · Clinical genitourinary cancer · 2026

Bone Metastases and Use of Bone Protective Agents for Metastatic Clear Cell Renal Cell Carcinoma: A Contemporary National Real-World Analysis.

Millan Braden, Ghosh Sunita, Basappa Naveen S, Wood Lori, Bhindi Bimal, Pouliot Frederic, Breau Rodney H, Finelli Antonio, Bansal Rahul K, Graham Jeffrey, Bjarnason Georg A, Bosse Dominick, Castonguay Vincent, Winquist Eric, Heng Daniel Yick Chin, Kollmannsberger Christian K, Lalani Aly-Khan A

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Bone Metastases (BM) are associated with a poor prognosis in metastatic clear-cell renal cell carcinoma (mccRCC). In the immune checkpoint inhibitor (IO) era, evidence for and use of bone-protective agents (BPAs) is limited. We investigated oncologic outcomes in mccRCC patients with BM at diagnosis and the use of BPA in a contemporary real-world cohort.

METHODS

We identified patients with mccRCC treated between 2011 and 2023. Adjusted Kaplan-Meier estimates were used to estimate time to treatment failure (TTF) and overall survival (OS), and cohort comparisons were performed using Cox proportional hazards model.

RESULTS

Of 2482 patients with mccRCC, 956 (38.5%) had BM at diagnosis, and 210 (22.0%) received a BPA. First-line tyrosine kinase inhibitor (TKI) containing regimen use was higher in BM + patients (79.3% vs. 74.9%). First-line median TTF was similar (9.4 vs. 8.7 mos); however, median OS was longer in BM- vs. BM + patients: 54.2 vs. 35.0 mos (HR, 1.32; P < .0001), irrespective of first-line therapy. BPA omission in BM + only patients resulted in a non-statistically significant shorter TTF (8.3 vs. 10.4 mos; HR, 0.91) and OS (34.3 vs. 38.5 mos; HR, 1.00). Receipt of first-line IO/IO (HR, 0.69; 0.60-0.81) and IO + TKI (HR, 0.61; 0.54-0.74) compared to monotherapy TKI resulted in a significantly longer OS in all patients, though not in BM + only patients.

CONCLUSIONS

BM remain a poor prognostic factor in mccRCC in this contemporary cohort. Despite more use in BM + patients, BPAs were not associated with improved TTF or OS, though their potential impact on skeletal-related events is not captured in the current study.

Для цитирования: Millan Braden, Ghosh Sunita, Basappa Naveen S, Wood Lori, Bhindi Bimal, Pouliot Frederic, Breau Rodney H, Finelli Antonio, Bansal Rahul K, Graham Jeffrey, Bjarnason Georg A, Bosse Dominick, Castonguay Vincent, Winquist Eric, Heng Daniel Yick Chin, Kollmannsberger Christian K, Lalani Aly-Khan A. Bone Metastases and Use of Bone Protective Agents for Metastatic Clear Cell Renal Cell Carcinoma: A Contemporary National Real-World Analysis.. Clinical genitourinary cancer. 2026. DOI: 10.1016/j.clgc.2026.102539.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.